Serplulimab for Advanced Lung Cancer in Older Adults
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug called serplulimab in patients aged 65 and older with advanced non-small cell lung cancer (NSCLC). The drug works by helping your immune system fight cancer cells that have a specific marker called PD-L1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years old or older
- You have advanced lung cancer (Stage IIIB, IIIC, or IV) that has been confirmed by biopsy or cell sample
- Your cancer cells show high levels of PD-L1 (≥50%), confirmed by a lab test
- Your cancer does not have certain genetic mutations (EGFR, ALK, or ROS1) that would make other treatments more appropriate
- You have not received immunotherapy drugs before (anti-PD-1, anti-PD-L1, or anti-CTLA-4)
- Your blood counts and organ function (kidney, liver) are adequate to safely receive the drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy and radiation for older adults with locally advanced esophageal cancer. It aims to see if this combination can help shrink tumors and improve outcomes without prior cancer treatment.
This trial tests whether adding an immunotherapy drug (Serplulimab) to chemotherapy before surgery can help people with advanced stage III non-small cell lung cancer that cannot be removed. It aims to shrink the tumor and improve outcomes.
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.